XTX Topco Ltd Makes New $42,000 Investment in Allurion Technologies, Inc. (NYSE:ALUR)

XTX Topco Ltd purchased a new position in shares of Allurion Technologies, Inc. (NYSE:ALUR) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 13,037 shares of the company’s stock, valued at approximately $42,000. XTX Topco Ltd owned approximately 0.27% of Allurion Technologies as of its most recent filing with the SEC.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ALUR. Wall Street Zen downgraded Allurion Technologies from a “hold” rating to a “strong sell” rating in a research note on Saturday. Zacks Research upgraded Allurion Technologies to a “hold” rating in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.83.

Allurion Technologies Price Performance

Shares of ALUR opened at $2.41 on Friday. The firm has a 50 day simple moving average of $2.71 and a two-hundred day simple moving average of $3.01. The company has a market cap of $17.94 million, a P/E ratio of -0.19 and a beta of -0.45. Allurion Technologies, Inc. has a one year low of $2.15 and a one year high of $22.25.

Allurion Technologies (NYSE:ALUR) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.53) by $1.96. The company had revenue of $5.58 million during the quarter, compared to analyst estimates of $5.50 million. On average, analysts expect that Allurion Technologies, Inc. will post -9.96 earnings per share for the current fiscal year.

Allurion Technologies Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.